WallStreetZenWallStreetZen

NASDAQ: GANX
Gain Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for GANX

Based on 2 analysts offering 12 month price targets for Gain Therapeutics Inc.
Min Forecast
$9.00+92.31%
Avg Forecast
$9.50+102.99%
Max Forecast
$10.00+113.68%

Should I buy or sell GANX stock?

Based on 2 analysts offering ratings for Gain Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GANX stock forecasts and price targets.

GANX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-12-04
lockedlocked$00.00+00.00%2023-09-12

1 of 1

Forecast return on equity

Is GANX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.11%

Forecast return on assets

Is GANX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

GANX revenue forecast

What is GANX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$500.0k+806.13%
Avg 2 year Forecast
$180.0k+226.21%
Avg 3 year Forecast
$230.0k+316.82%
GANX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GANX revenue growth forecast

How is GANX forecast to perform vs Biotechnology companies and vs the US market?
Company
42.78%
Industry
45.89%
Market
10.82%
GANX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GANX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GANX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GANX$4.68$9.50+102.99%Strong Buy
CGTX$2.00N/AN/A
VERU$0.64$2.00+212.50%Buy
ENLV$3.21$12.00+273.83%Buy
CLGN$5.21$11.00+111.13%Buy

Gain Therapeutics Stock Forecast FAQ

Is Gain Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: GANX) stock is to Strong Buy GANX stock.

Out of 2 analysts, 1 (50%) are recommending GANX as a Strong Buy, 1 (50%) are recommending GANX as a Buy, 0 (0%) are recommending GANX as a Hold, 0 (0%) are recommending GANX as a Sell, and 0 (0%) are recommending GANX as a Strong Sell.

If you're new to stock investing, here's how to buy Gain Therapeutics stock.

What is GANX's revenue growth forecast for 2024-2026?

(NASDAQ: GANX) Gain Therapeutics's forecast annual revenue growth rate of 42.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.82%.

Gain Therapeutics's revenue in 2024 is $55,180.On average, 3 Wall Street analysts forecast GANX's revenue for 2024 to be $6,455,171, with the lowest GANX revenue forecast at $2,194,758, and the highest GANX revenue forecast at $12,910,342. On average, 1 Wall Street analysts forecast GANX's revenue for 2025 to be $2,323,862, with the lowest GANX revenue forecast at $2,323,862, and the highest GANX revenue forecast at $2,323,862.

In 2026, GANX is forecast to generate $2,969,379 in revenue, with the lowest revenue forecast at $2,969,379 and the highest revenue forecast at $2,969,379.

What is GANX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GANX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GANX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year GANX price target, the average GANX price target is $9.50, with the highest GANX stock price forecast at $10.00 and the lowest GANX stock price forecast at $9.00.

On average, Wall Street analysts predict that Gain Therapeutics's share price could reach $9.50 by Dec 4, 2024. The average Gain Therapeutics stock price prediction forecasts a potential upside of 102.99% from the current GANX share price of $4.68.

What is GANX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GANX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.